| PNS Notification from Sedgwick | |
| Initiated by : Grifols Therapeutics LLC Event Id : 218 Event Date : 01-24-2025 |
![]() |
| Therapy |
|
|||||||||||||||
| Reason | This is to inform you that Grifols Therapeutics is initiating a voluntary withdrawal of one lot of XEMBIFY, 20% 4G VIAL as detailed below. Grifols is committed to providing the highest quality medicines in the market. This voluntary withdrawal is being conducted as a precautionary measure due to an increased rate of allergic/hypersensitivity type reactions associated with this specific lot. A small number of the reactions were considered medically significant. Hypersensitivity and anaphylactic/anaphylactoid reactions are a known risk with immune globulin products. |
|||||||||||||||
| Action | Please examine your stock immediately to determine if you have any of the above-mentioned lots on hand. If you have product from this lot, cease use of the product immediately. Return the affected product to the point of purchase to receive replacement product. |
|||||||||||||||
| Other Information | If you have any technical or clinical questions, please contact US Clinical Communications at (800) 520-2807. | |||||||||||||||